Mike Freeman
Lung cancer is the largest single contributor to cancer deaths worldwide: 85% of lung cancers are classified as non-small cell lung cancer (NSCLC), and for patients who present with locally advanced stage IIB/III disease the standard of care is concurrent chemoradiation therapy. Unfortunately, this approach only yields a median survival of 17 months. Dr. Michael L. Freeman of the Department of Radiation Oncology at Vanderbilt University School of Medicine and Cumberland Emerging Technologies have partnered to develop a formulated version of a novel radio and chemo sensitizing compound that targets NPM1 for the treatment of NSCLC stage IIB/III disease. Dr. Freeman’s lab is using various approaches to develop a clinically efficacious formulation.
Lung cancer is the largest single contributor to cancer deaths worldwide: 85% of lung cancers are classified as non-small cell lung cancer (NSCLC), and for patients who present with locally advanced stage IIB/III disease the standard of care is concurrent chemoradiation therapy. Unfortunately, this approach only yields a median survival of 17 months. Dr. Michael L. Freeman of the Department of Radiation Oncology at Vanderbilt University School of Medicine and Cumberland Emerging Technologies have partnered to develop a formulated version of a novel radio and chemo sensitizing compound that targets NPM1 for the treatment of NSCLC stage IIB/III disease. Dr. Freeman’s lab is using various approaches to develop a clinically efficacious formulation.
Keywords: Non-small cell lung cancer , Radiation Therapy , Radiation Sensitization , Nucleophosmin1 , DNA double strand break repair
Research Area: Drug Design , Cancer Biology